DR. PATRICK GRIERSON MD NPI 1720492192

NPI Details

DR. Patrick Grierson, MD is a medical oncology internal medicine in Saint Louis, MO with 11 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Patrick Grierson, MD NPI is 1720492192. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: OHIO STATE UNIVERSITY COLLEGE OF MEDICINE
Graduation Year:2014

The provider's business location address is:

10 BARNES WEST DR
DIV IM MEDICAL ONCOLOGY, MOB #2
SAINT LOUIS, MO
ZIP 63141-287
Phone: (800) 647-2098
Fax: (314) 362-3192

The NPI 1720492192 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1561)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Unclassified drugs (HCPCS:J3490)
• Collection of blood sample from implanted device (HCPCS:36591)
• Transfusion of blood or blood products (HCPCS:36430)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Red blood cells, leukocytes reduced, irradiated, each unit (HCPCS:P9040)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)

The enumeration date for this NPI number is 6/13/2014 and was last updated on 4/25/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.